KRAS and Miyoshi myopathy: Interestingly, KRAS mutant MM xenograft models (MM.1S and RPMI-8226) are highly sensitive to ixazomib [38],[39], suggesting that the PI-resistance of KRAS mutant tumors is indication specific.